
Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
108.510
Open
107.100
VWAP
107.95
Vol
614.64K
Mkt Cap
3.80B
Low
105.782
Amount
66.35M
EV/EBITDA(TTM)
13.93
Total Shares
33.50M
EV
5.01B
EV/OCF(TTM)
23.86
P/S(TTM)
2.16
Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
471.60M
+7.82%
1.594
+21.65%
488.60M
+8.7%
1.826
+27.68%
467.72M
+8.41%
1.673
+17%
Estimates Revision
The market is revising No Change the revenue expectations for Integer Holdings Corporation (ITGR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -11.62%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+0.44%
In Past 3 Month
Stock Price
Go Down

-11.62%
In Past 3 Month
8 Analyst Rating

36.24% Upside
Wall Street analysts forecast ITGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITGR is 147.83 USD with a low forecast of 140.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy

36.24% Upside
Current: 108.510

Low
140.00
Averages
147.83
High
155.00

36.24% Upside
Current: 108.510

Low
140.00
Averages
147.83
High
155.00
BofA
analyst
Buy
downgrade
$158 -> $135
2025-07-25
New
Reason
BofA
analyst
Price Target
$158 -> $135
2025-07-25
New
downgrade
Buy
Reason
BofA lowered the firm's price target on Integer to $135 from $158 and keeps a Buy rating on the shares. Despite "strong" Q2 results and the company raising its FY25 EPS guidance by 5c at the midpoint, shares were down 8% yesterday, notes the analyst, who thinks investors were likely disappointed that Integer only narrowed its FY25 revenue guide with no change to midpoint after the Q2 beat. The firm lowers its price target as peer multiples have compressed, but highlights Integer as "a key manufacturing partner to customers in the highest growth medtech markets."
Raymond James
Outperform
downgrade
$150 -> $143
2025-07-25
New
Reason
Raymond James
Price Target
$150 -> $143
2025-07-25
New
downgrade
Outperform
Reason
Raymond James lowered the firm's price target on Integer to $143 from $150 and keeps an Outperform rating on the shares. Despite the solid quarter, the stock closed down 7.5%, which Raymond James believes is an overreaction. The outlooks for EBIT and EPS are improved and Raymond James views the pullback as a buying opportunity.
Citi
Neutral -> Buy
upgrade
$133 -> $140
2025-05-22
Reason
Citi
Price Target
$133 -> $140
2025-05-22
upgrade
Neutral -> Buy
Reason
Robert Wasserman
Buy
maintain
$150 -> $140
2025-04-25
Reason
Robert Wasserman
Price Target
$150 -> $140
2025-04-25
maintain
Buy
Reason
Benchmark analyst Robert Wasserman lowered the firm's price target on Integer to $140 from $150 and keeps a Buy rating on the shares. Updated financial guidance for FY25 included revenues of $1.846B-$1.88B, the same as previously, and adjusted EPS of $6.15-$6.51, which is an increase, notes the analyst, who cites reduced valuation metrics for comparable stocks for the firm's lower target after Integer reported better-than-expected results for its Q1.
Raymond James
Outperform
maintain
$145 -> $150
2025-04-25
Reason
Raymond James
Price Target
$145 -> $150
2025-04-25
maintain
Outperform
Reason
Raymond James raised the firm's price target on Integer to $150 from $145 and keeps an Outperform rating on the shares. Integer had a "strong" Q1 print, and the firm tells investors in a research note that reiterated guidance outside interest savings from the recent convert offering screens somewhat conservative. Modest upside thus far positions the company for a shot to break par through the rest of the year, the firm says.
Truist
Richard Newitter
Buy
maintain
$140 -> $150
2025-04-25
Reason
Truist
Richard Newitter
Price Target
$140 -> $150
2025-04-25
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on Integer to $150 from $140 and keeps a Buy rating on the shares. Integer beat estimates in Q1 on EPS and organic revenue amid strength in Cardio and Vascular, and guidance for 8%-10% organic growth for fiscal 2025 was reiterated, while EPS guidance was increased, the analyst tells investors in a research note. Truist thinks the outlook leaves room for upside as the year progresses and continues to believe that the company can profitably grow above its end markets.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Integer Holdings Corp (ITGR.N) is 16.23, compared to its 5-year average forward P/E of 19.94. For a more detailed relative valuation and DCF analysis to assess Integer Holdings Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
19.94
Current PE
16.23
Overvalued PE
22.81
Undervalued PE
17.08
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
13.26
Current EV/EBITDA
12.68
Overvalued EV/EBITDA
14.63
Undervalued EV/EBITDA
11.89
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
2.03
Current PS
2.12
Overvalued PS
2.37
Undervalued PS
1.69
Financials
Annual
Quarterly
FY2025Q2
YoY :
+9.24%
476.49M
Total Revenue
FY2025Q2
YoY :
+11.66%
63.92M
Operating Profit
FY2025Q2
YoY :
+18.44%
37.01M
Net Income after Tax
FY2025Q2
YoY :
+18.18%
1.04
EPS - Diluted
FY2025Q2
YoY :
+54.82%
24.86M
Free Cash Flow
FY2025Q2
YoY :
-0.18%
27.41
Gross Profit Margin - %
FY2025Q2
YoY :
+67.74%
6.76
FCF Margin - %
FY2025Q2
YoY :
+8.52%
7.77
Net Margin - %
FY2025Q2
YoY :
-29.95%
4.00
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
44.6M
USD
3
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
21.6K
Volume
Months
6-9
1
45.2K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
44.6M
USD
3
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ITGR News & Events
Events Timeline
2025-07-24 (ET)
2025-07-24
08:03:24
Integer sees FY25 adjusted EPS $6.25-$6.51, consensus $6.31

2025-07-24
08:03:12
Integer reports Q2 adjusted EPS $1.55, consensus $1.55

2025-04-24 (ET)
2025-04-24
08:07:34
Integer CEO Joseph Dziedzic to retire, Payman Khales to succeed

Sign Up For More Events
Sign Up For More Events
News
9.5
07-25NASDAQ.COMInteger Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y
3.0
07-23Yahoo FinanceWhat To Expect From Integer Holdings’s (ITGR) Q2 Earnings
2.0
07-18Yahoo FinanceThermo Fisher, Exact Sciences, Integer Holdings, Revvity, and 10x Genomics Shares Are Falling, What You Need To Know
Sign Up For More News
People Also Watch

EXPO
Exponent Inc
72.230
USD
+0.14%

IEP
Icahn Enterprises LP
9.360
USD
-0.11%

WTM
White Mountains Insurance Group Ltd
1789.580
USD
+0.66%

SLG
SL Green Realty Corp
60.650
USD
+2.17%

LANC
Lancaster Colony Corp
0
USD
+0.56%

NJR
New Jersey Resources Corp
45.960
USD
+0.15%

CAMT
Camtek Ltd
95.810
USD
+1.67%

SON
Sonoco Products Co
48.330
USD
-0.51%

MUR
Murphy Oil Corp
26.130
USD
-0.76%

MMS
Maximus Inc
73.450
USD
-0.24%
FAQ

What is Integer Holdings Corp (ITGR) stock price today?
The current price of ITGR is 108.51 USD — it has increased 1.32 % in the last trading day.

What is Integer Holdings Corp (ITGR)'s business?

What is the price predicton of ITGR Stock?

What is Integer Holdings Corp (ITGR)'s revenue for the last quarter?

What is Integer Holdings Corp (ITGR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Integer Holdings Corp (ITGR)'s fundamentals?

How many employees does Integer Holdings Corp (ITGR). have?
